Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPERIUM individualized treatment study in older patients with type 2 diabetes
2013-001473-24Phase 4Terminated
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2013
- Modality
- Small Molecules, Peptides, Microbiome-Derived Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of metformin, pioglitazone, acarbose, linagliptin, sitagliptin and 4 more in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Primary composite outcome. Started Nov 2013; status: terminated.
02
Drugs
metforminpioglitazoneacarboselinagliptinsitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2013-001473-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001473-24.